Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more
Catalyst Pharmaceuticals Inc (CPRX) - Total Assets
Latest total assets as of December 2025: $1.11 Billion USD
Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) holds total assets worth $1.11 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Catalyst Pharmaceuticals Inc - Total Assets Trend (2002–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Catalyst Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Catalyst Pharmaceuticals Inc's total assets of $1.11 Billion consist of 80.8% current assets and 19.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.1% |
| Accounts Receivable | $128.27 Million | 11.6% |
| Inventory | $37.17 Million | 3.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $131.67 Million | 11.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Catalyst Pharmaceuticals Inc's current assets represent 80.8% of total assets in 2025, a decrease from 96.0% in 2002.
- Cash Position: Cash and equivalents constituted 64.1% of total assets in 2025, down from 96.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 11.9% of total assets.
Catalyst Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Catalyst Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Catalyst Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Catalyst Pharmaceuticals Inc generates 0.53x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Catalyst Pharmaceuticals Inc generates $ 19.36 in net profit.
Catalyst Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.08 | 5.17 | 11.19 |
| Quick Ratio | 5.82 | 5.01 | 10.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $746.88 Million | $ 502.93 Million | $ 147.10 Million |
Catalyst Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Catalyst Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.10 |
| Latest Market Cap to Assets Ratio | 2.41 |
| Asset Growth Rate (YoY) | 30.0% |
| Total Assets | $1.11 Billion |
| Market Capitalization | $2.67 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Catalyst Pharmaceuticals Inc's assets at a significant premium ( 2.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Catalyst Pharmaceuticals Inc's assets grew by 30.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Catalyst Pharmaceuticals Inc (2002–2025)
The table below shows the annual total assets of Catalyst Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.11 Billion | +30.00% |
| 2024-12-31 | $851.41 Million | +81.11% |
| 2023-12-31 | $470.11 Million | +25.15% |
| 2022-12-31 | $375.63 Million | +57.97% |
| 2021-12-31 | $237.79 Million | +23.62% |
| 2020-12-31 | $192.35 Million | +71.17% |
| 2019-12-31 | $112.38 Million | +85.90% |
| 2018-12-31 | $60.45 Million | -29.21% |
| 2017-12-31 | $85.39 Million | +104.73% |
| 2016-12-31 | $41.71 Million | -30.61% |
| 2015-12-31 | $60.10 Million | +36.88% |
| 2014-12-31 | $43.91 Million | +73.07% |
| 2013-12-31 | $25.37 Million | +51.11% |
| 2012-12-31 | $16.79 Million | +168.66% |
| 2011-12-31 | $6.25 Million | +7.16% |
| 2010-12-31 | $5.83 Million | -26.80% |
| 2009-12-31 | $7.97 Million | -33.80% |
| 2008-12-31 | $12.03 Million | -27.86% |
| 2007-12-31 | $16.68 Million | -19.11% |
| 2006-12-31 | $20.62 Million | +2511.88% |
| 2005-12-31 | $789.45K | +325.86% |
| 2004-12-31 | $185.38K | +66.12% |
| 2002-12-31 | $111.59K | -- |